Trade

with

Medivation Inc
(NASDAQ: MDVN)
AdChoices
101.87
+2.47
+2.48%
After Hours :
101.87
0.00
0.00%

Open

99.41

Previous Close

99.40

Volume (Avg)

758.48k (1.15M)

Day's Range

99.28-102.16

52Wk Range

54.37-103.88

Market Cap.

7.82B

Dividend Rate ( Yield )

-

Beta

0.76

Shares Outstanding

76.79M

P/E Ratio (EPS)

333.33 (0.30)

AdChoices
Financials
  • Income Statement
  • Balance Sheet
  • Cash Flow
Operating Income
-22.24M
Operating Margin
-8.15
Total Equity
-
Retained Earnings
-
Free Cashflow
-
Price/Cashflow
-
Ownership

Institutional Ownership

98.87%

Top 10 Institutions

45.85%

Mutual Fund Ownership

57.76%

Float

84.42%

5% / Insider Ownership

2.69%

Corporate insiders or major stockholders reporting trading activity in the stock.

Top Mutual Fund Owners

Top Institutional Owners

Mutual Fund Name

Institution Name

  • Mutual Fund Name

  • Shares Held

  • % Change

  • % Outstanding

  • Fidelity® Select Biotechnology Portfolio

  •  

    2,433,685

  • 0.00

  • 3.17

  • Franklin Biotechnology Discovery

  •  

    2,116,100

  • 84.62

  • 2.77

  • Bb Biotech AG

  •  

    1,429,706

  • -4.67

  • 1.86

  • Vanguard Small Cap Index

  •  

    1,267,152

  • 0.01

  • 1.65

  • Vanguard Total Stock Mkt Idx

  •  

    1,184,552

  • 0.19

  • 1.54

  • iShares Nasdaq Biotechnology

  •  

    992,342

  • -0.47

  • 1.30

  • Wells Fargo Advantage Growth Fund

  •  

    977,803

  • 11.39

  • 1.27

  • Vanguard Small Cap Growth Index Fund

  •  

    856,506

  • -1.97

  • 1.12

  • Fidelity® Independence Fund

  •  

    842,100

  • 0.00

  • 1.10

  • Franklin US Opportunities

  •  

    773,000

  • 74.61

  • 1.01

  • Institution Name

  • Shares Held

  • % Change

  • % Outstanding

  • Fidelity Management and Research Company

  •  

    6,315,798

  • -19.81%

  • 8.23

  • Franklin Advisers, Inc.

  •  

    4,615,299

  • +4.31%

  • 6.02

  • Janus Capital Management LLC

  •  

    4,497,073

  • +1.35%

  • 5.86

  • Vanguard Group, Inc.

  •  

    4,392,324

  • -3.55%

  • 5.73

  • Adage Capital Partners Gp LLC

  •  

    3,972,060

  • -14.80%

  • 5.18

  • Blair William & Co

  •  

    2,458,698

  • +0.38%

  • 3.21

  • Orbimed Advisors, LLC

  •  

    2,446,600

  • -10.19%

  • 3.19

  • Knoll Capital Management LP

  •  

    2,279,519

  • 0.00%

  • 2.97

  • Pyramis Global Advisors, LLC

  •  

    2,158,233

  • -4.23%

  • 2.81

  • Wellington Management Company, LLP

  •  

    2,030,132

  • -10.39%

  • 2.65

Company Profile

Sector

Healthcare

Industry

Biotechnology

Type

Speculative Growth

Style

Mid Growth

Medivation, Inc was formed in Delaware in October 1995. The Company is a biopharmaceutical company engaged in the rapid development of novel small molecule drugs to treat diseases for which there are limited treatment options. Togeth...moreer with its collaboration partner Astellas Pharma Inc., or Astellas, the Company is developing XTANDI "enzalutamide" capsules. Together with Astellas, it is also conducting multiple trials of enzalutamide in earlier prostate cancer disease states, including the Phase 3 PREVAIL trial in patients with mCRPC who have not received chemotherapy, or pre-chemotherapy mCRPC patients, and in patients with breast cancer. Based on the positive results of the AFFIRM trial, the Company has exercised its right under its collaboration agreement with Astellas to co-promote XTANDI in the...more U.S., should it receive marketing approval. Their subsidiaries are Medivation Prostate Therapeutics, Inc., or MPT, Medivation Neurology, Inc., or MNI, Medivation Technologies, Inc., or MTI, Medivation Field Solutions, Inc., or MFSI, and Medivation Services, Inc., or MSI. MPT holds the intellectual property rights covering XTANDI. MNI holds the intellectual property rights covering dimebon, which was in development for Alzheimer’s disease and Huntington disease under its former collaboration with Pfizer. MTI holds the intellectual property rights covering its early-stage technologies. MFSI provides commercialization services to the Company, and MSI provides research and development services. It has received “Fast Track” designation from the U.S. Food and Drug Administration for the post-docetaxel indication. The Company is conducting this program in collaboration with Astellas. The Company is subject to extensive regulation by the Federal Food, Drug, and Cosmetic Act, or the FDC Act, and other federal and state statutes and regulations, govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, approval, labeling, promotion and marketing, distribution, post-approval monitoring and reporting, sampling, and import and export of pharmaceutical products.lessless

Key People

Dr. David T. Hung,M.D.

CEO/Co-Founder/Director/President

Kim D. Blickenstaff

Director/Chairman of the Board

Rick Bierly

Chief Accounting Officer/CFO

C. Patrick Machado

Director

Kathryn E. Falberg

Director

Incorporated

1995

Employees

-

Send Feedback

We appreciate your input!

  • I'm having trouble signing into my Microsoft account

  • I’m having problems with the services stripe (Mail, Facebook, etc.)

  • There is an issue with my weather information

  • I see an error in the content

  • Other

Please give an overall site rating: